Latest News About - Medical Devices Adverse Effects

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Monday, March 27, 2017

4:48:00 AM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
lb
lo
lt
lv
mk
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Quotes... Extracted quotes

Richard Pazdur said: “While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell cancer have not had an approved treatment option until now,” External link

healthcanal Friday, March 24, 2017 10:16:00 AM CET

Richard Pazdur said: “While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell cancer have not had an approved treatment option until now,” External link

fda Thursday, March 23, 2017 7:42:00 PM CET

Stuart Schweitzer said: “I see the pharmaceutical industry as extraordinarily vulnerable to failure,” “It’s a very high-risk business. Something like 10 percent of all drugs that are developed get FDA approval. Merck, a couple of years ago, had a drug for inhaled insulin that cost about $2 billion. It was even approved by the FDA, and nobody bought it. It was a failure. They closed it down and sold their patent rights” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Stuart Schweitzer said: “I’d like to see legislation that would have the FDA lighten up on the approval regulations,” “So when a drug price has increased by more than, say, 50 percent in a year, the FDA could scare manufacturers away from doing this by ensuring that there’s going to be [a competing product] in the marketplace quite soon. So my answer lies on the supply side, and definitely not price controls, because I don’t believe that we’re going to get as much drug discovery if we take away the motive of making money with a few of our successful drugs” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Stuart Schweitzer says: “An example of that is the EpiPen,” “How did they get away with raising their price, and nobody came in and underbid them? You’ve got to look at the FDA’s devices section. The drug in the EpiPen, epinephrine, is a generic drug. There’s no secret to it. The secret is in the delivery system itself. How is it that Mylan developed a really good medical device and nobody else could do that? The FDA devices section takes three years to approve a device, and that really hurt a lot of people. So now there is competition in the market for the EpiPen, but it shouldn’t have taken that long” External link

healthlinenews Thursday, March 23, 2017 7:13:00 PM CET

Mark Miller said: “In the interest of patient safety, it is premature to reach a conclusion regarding the cause,” External link

latimes Thursday, March 23, 2017 5:45:00 PM CET

Anna Jones said: "Elvie is already spearheading a massive consumer shift towards female-focused technology," External link

telegraph Thursday, March 23, 2017 5:06:00 AM CET

Christian Albring erklärt: «Die natürliche Verhütung basiert auf der Tatsache, dass sich die Körpertemperatur mit dem Eisprung um 0,2 bis 0,5 Grad erhöht und bis kurz vor der Menstruation erhöht bleibt» External link

rheinpfalz Wednesday, March 22, 2017 5:06:00 AM CET

Cecilia Edström säger: – Det här kommer på sikt att kunna hjälpa många svårt sjuka patienter, External link

lifesciencesweden Tuesday, February 7, 2017 11:23:00 AM CET

Cecilia Edström säger: – Genom att kombinera Smartwises avancerade mikrokatetrar och Bactiguards ytskiktsteknologi kommer svårt sjuka patienter att kunna få ta del av nya behandlingsmöjligheter. Möjligheterna att administrera läkemedel till delar av kroppen som tidigare har varit svåråtkomliga och mycket känsliga kommer att öka – det här är ett mycket lovande samarbete, External link

lifesciencesweden Tuesday, February 7, 2017 11:23:00 AM CET

Jonathan Clarke förklarar: – Det här är verkligen ett genombrott som kommer att kunna få många olika användningsområden. Det kommer kunna bli möjligt att administrerar en rad olika läkemedel till tidigare svåråtkomliga och känsliga delar av kroppen. Till exempel kommer den nya teknologin att kunna administrera cytostatika i höga doser direkt till svåråtkomliga tumörer, External link

lifesciencesweden Tuesday, February 7, 2017 11:23:00 AM CET

Cecilia Edström säger: – För 1,5 år sedan fattade vi beslutet att i större utsträckning utveckla möjligheterna till fler licensavtal för vår teknologi. Initialt har vi fokuserat mycket på ortopediska implantat där kliniska studier nu pågår och nu har vi slutit licensavtal med Smartwise. Men vi ser absolut att vår teknologi kan komma till användning inom ytterligare terapiområden i framtiden, External link

lifesciencesweden Tuesday, February 7, 2017 11:23:00 AM CET

Jonathan Clarke säger: – De första kliniska testerna kommer troligen att äga rum i Sverige och andra delar av Europa. Vi är ett svenskt bolag och vi vill vara med och gynna svensk bioteknik, External link

lifesciencesweden Tuesday, February 7, 2017 11:23:00 AM CET

Most associated names

Daily number of articles in this category

Trend data not available for this selection.